Deacetylase Plus Bromodomain Inhibition Downregulates ERCC2 and Suppresses the Growth of Metastatic Colon Cancer Cells.
BET inhibition
DNA repair
HDAC inhibition
JQ1
PROTAC
colorectal cancer
epigenetic
nucleotide excision repair
polyposis in rat colon
sulforaphane
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Mar 2021
22 Mar 2021
Historique:
received:
10
03
2021
accepted:
19
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
There is growing evidence that DNA repair factors have clinical value for cancer treatment. Nucleotide excision repair (NER) proteins, including excision repair cross-complementation group 2 (ERCC2), play a critical role in maintaining genome integrity. Here, we examined ERCC2 expression following epigenetic combination drug treatment. Attention was drawn to ERCC2 for three reasons. First, from online databases, colorectal cancer (CRC) patients exhibited significantly reduced survival when
Identifiants
pubmed: 33809839
pii: cancers13061438
doi: 10.3390/cancers13061438
pmc: PMC8004213
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : R01 CA122959
Pays : United States
Organisme : Division of Cancer Prevention, National Cancer Institute
ID : CA090890 and CA122959
Organisme : John S. Dunn Foundation
ID : NA
Références
Mol Cell. 2001 Jul;8(1):213-24
pubmed: 11511374
Adv Cancer Res. 2012;116:87-129
pubmed: 23088869
Clin Cancer Res. 2019 Feb 1;25(3):977-988
pubmed: 29980530
EMBO J. 1997 Nov 3;16(21):6559-73
pubmed: 9351836
Nat Commun. 2016 Aug 09;7:12364
pubmed: 27503537
Nat Rev Cancer. 2008 Mar;8(3):193-204
pubmed: 18256616
Pharmacogenet Genomics. 2009 Jul;19(7):563-4
pubmed: 19525887
Mol Nutr Food Res. 2018 Sep;62(18):e1800228
pubmed: 29924908
Clin Epigenetics. 2012 Sep 24;4(1):16
pubmed: 23006636
Clin Epigenetics. 2011;3(1):4
pubmed: 22247744
Front Mol Biosci. 2018 Mar 20;5:23
pubmed: 29616226
Sci Rep. 2014 Oct 01;4:6468
pubmed: 25270048
Cancer Prev Res (Phila). 2020 Dec 4;:
pubmed: 33277315
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 5;372(1731):
pubmed: 28847823
Oncol Lett. 2020 Nov;20(5):212
pubmed: 32963618
Nat Rev Genet. 2007 Oct;8(10):735-48
pubmed: 17768402
Int J Cancer. 2017 Jan 15;140(2):460-468
pubmed: 27706811
Mol Cancer Res. 2005 Jun;3(6):345-53
pubmed: 15972853
Physiology (Bethesda). 2017 Jul;32(4):266-277
pubmed: 28615311
Int J Cancer. 2011 Jun 1;128(11):2581-90
pubmed: 20715105
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4036-41
pubmed: 17360473
Cold Spring Harb Perspect Biol. 2013 Oct 01;5(10):a012609
pubmed: 24086042
Cancer Res. 2019 Mar 1;79(5):918-927
pubmed: 30643017
Oncogene. 2001 Apr 5;20(15):1803-15
pubmed: 11313928
Cells. 2020 Mar 21;9(3):
pubmed: 32245194
Cancer Sci. 2020 Oct;111(10):3416-3425
pubmed: 33403784
Epigenetics. 2013 Jun;8(6):612-23
pubmed: 23770684
Mol Cancer. 2011 May 30;10:68
pubmed: 21624135
Nature. 2001 May 17;411(6835):366-74
pubmed: 11357144
Annu Rev Biochem. 2004;73:39-85
pubmed: 15189136
Biotechniques. 2008 Feb;44(2):ix-xiv
pubmed: 18422490
DNA Repair (Amst). 2016 Aug;44:136-142
pubmed: 27262611
Mol Cancer. 2018 Nov 22;17(1):164
pubmed: 30466442
Sci Rep. 2015 Sep 14;5:13987
pubmed: 26365200
J Cancer Prev. 2020 Dec 30;25(4):189-203
pubmed: 33409252
Nat Med. 2015 Oct;21(10):1163-71
pubmed: 26390243